Qpex Biopharma closed a $33 million Series A financing round and launched its infectious disease company. New Enterprise Associates led the financing syndicate featuring Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, and Stanford University Draper Fund. Additional funding is being provided through an agreement
Bioengineering startup Glympse Bio, Inc., raised $22 million in a Series A funding round co-led by venture capital firms LS Polaris Innovation Fund and ARCH Ventures. In addition, new investors Charles River Ventures, Gilead Sciences, Yonghua Capital, and Inevitable Ventures were joined by existing investors
Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases, raised a $30 million Series A investment led by F-Prime Capital Partners and OrbiMed. Modis is advancing its lead experimental therapy, MT1621, as a treatment for thymidine kinase 2 deficiency (TK2d), a
nference, an artificial intelligence powered life sciences startup, completed an $11 million Series A financing round led by Matrix Partners, with participation from existing investor Matrix Capital Management. The nference team works with pharmaceutical partners to identify disease processes with unmet need, stratify patients in
Alveo Technologies, Inc., announced the closing of a $38 million Series A financing led by Maxim Merchant Capital, a division of investment banking firm Maxim Group LLC. Alveo is on a mission to create a new ecosystem for the detection of infectious diseases by combining